TransMedics Group (NASDAQ:TMDX) Now Covered by Evercore ISI

Key Points

• Evercore ISI has initiated coverage on TransMedics Group (NASDAQ:TMDX) with an "outperform" rating and a price target of $155.00, indicating a potential upside of 35.62% from its previous close.
• Analysts have a mixed outlook on the stock, with one Strong Buy, six Buy, and four Hold ratings, resulting in an average rating of "Moderate Buy" and a price target of $125.40.
• TransMedics Group recently reported an earnings per share of $0.92 for the last quarter, significantly exceeding analysts' expectations of $0.48, with revenue growing 37.7% year-over-year.

Investment analysts at Evercore ISI assumed coverage on shares of TransMedics Group (NASDAQ:TMDX - Get Free Report) in a report issued on Tuesday. The firm set an "outperform" rating and a $155.00 price target on the stock. Evercore ISI's target price would suggest a potential upside of 35.62% from the stock's previous close.

Several other research firms also recently commented on TMDX. Wall Street Zen downgraded TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Canaccord Genuity Group increased their price objective on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Piper Sandler reissued an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Morgan Stanley increased their price objective on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Finally, Oppenheimer increased their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $125.40.

TransMedics Group Trading Down 0.2%

NASDAQ:TMDX opened at $114.29 on Tuesday. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $169.29. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The business has a 50 day moving average price of $115.93 and a two-hundred day moving average price of $106.02. The company has a market cap of $3.90 billion, a P/E ratio of 59.22 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. During the same quarter in the prior year, the firm posted $0.35 EPS. The business's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, analysts expect that TransMedics Group will post 1 EPS for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently added to or reduced their stakes in the business. Amalgamated Bank raised its stake in TransMedics Group by 0.8% in the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company's stock valued at $1,285,000 after acquiring an additional 80 shares during the period. Canada Pension Plan Investment Board raised its stake in TransMedics Group by 2.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock valued at $482,000 after acquiring an additional 100 shares during the period. Smartleaf Asset Management LLC raised its stake in TransMedics Group by 24.5% in the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company's stock valued at $72,000 after acquiring an additional 108 shares during the period. Ameritas Investment Partners Inc. raised its stake in TransMedics Group by 4.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company's stock valued at $455,000 after acquiring an additional 142 shares during the period. Finally, Franklin Resources Inc. raised its stake in TransMedics Group by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,842 shares of the company's stock valued at $1,989,000 after acquiring an additional 148 shares during the period. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.